INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
INmune Bio, Inc. (NASDAQ: INMB) announced that President and CEO Raymond J. Tesi will present at the Canaccord Genuity 41st Annual Growth Conference from August 10 to 12, 2021. Tesi's presentation is scheduled for August 11, 2021, at 9:00 AM ET. The conference will also allow for virtual one-on-one meetings with INmune Bio representatives. The company focuses on developing treatments to enhance the innate immune system to combat diseases, with key product platforms aimed at various conditions including COVID-19, cancer, and Alzheimer's.
- None.
- None.
BOCA RATON, Florida, Aug. 10, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will present at the Canaccord Genuity 41st Annual Growth Conference being held August 10 – 12.
Canaccord Genuity 41st Annual Growth Conference
Presentation Date: Wednesday, August 11, 2021
Presentation Time: 9:00 AM Eastern Time
Webcast: https://wsw.com/webcast/canaccord60/inmb/2433112
Please contact your representative at Canaccord Genuity to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720
DMoss@INmuneBio.com
Investor Contact:
Chuck Padala
LifeSci Advisors
(646) 627-8390
chuck@lifesciadvisors.com
Media Contact:
Michael Tattory
LifeSci Communications
609-802-6265
mtattory@lifescicomms.com
FAQ
When is INmune Bio's presentation at the Canaccord Genuity 41st Annual Growth Conference?
Who is presenting for INmune Bio at the conference?
What is the focus of INmune Bio's treatments?
How can investors schedule a meeting with INmune Bio during the conference?
What are the main disease targets for INmune Bio's product platforms?
